ES2611776T3 - Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos - Google Patents

Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos Download PDF

Info

Publication number
ES2611776T3
ES2611776T3 ES14701067.2T ES14701067T ES2611776T3 ES 2611776 T3 ES2611776 T3 ES 2611776T3 ES 14701067 T ES14701067 T ES 14701067T ES 2611776 T3 ES2611776 T3 ES 2611776T3
Authority
ES
Spain
Prior art keywords
treatment
female sterility
diabetic mammals
tungsten salts
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14701067.2T
Other languages
English (en)
Inventor
Ignacio CANALS ALMAZÁN
Agnès ARBAT BUGIÉ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxolife SL
Original Assignee
Oxolife SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49999950&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2611776(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxolife SL filed Critical Oxolife SL
Application granted granted Critical
Publication of ES2611776T3 publication Critical patent/ES2611776T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physiology (AREA)

Abstract

Sal de tungsteno (VI) con un grupo catiónico farmacéutica o veterinariamente aceptable, o un solvato de la misma para su uso en el tratamiento de la esterilidad femenina en mamíferos no diabéticos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES14701067.2T 2013-01-22 2014-01-21 Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos Active ES2611776T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201330071A ES2478790B1 (es) 2013-01-22 2013-01-22 Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos
ES201330071 2013-01-22
PCT/EP2014/051141 WO2014114644A1 (en) 2013-01-22 2014-01-21 Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals

Publications (1)

Publication Number Publication Date
ES2611776T3 true ES2611776T3 (es) 2017-05-10

Family

ID=49999950

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201330071A Active ES2478790B1 (es) 2013-01-22 2013-01-22 Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos
ES14701067.2T Active ES2611776T3 (es) 2013-01-22 2014-01-21 Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES201330071A Active ES2478790B1 (es) 2013-01-22 2013-01-22 Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos

Country Status (27)

Country Link
US (1) US9675638B2 (es)
EP (1) EP2948156B1 (es)
JP (1) JP6045721B2 (es)
KR (1) KR102182563B1 (es)
CN (1) CN105188721B (es)
AU (1) AU2014209987B2 (es)
BR (1) BR112015017483A2 (es)
CA (1) CA2898953C (es)
CL (1) CL2015002047A1 (es)
CY (1) CY1118287T1 (es)
DK (1) DK2948156T3 (es)
ES (2) ES2478790B1 (es)
HK (1) HK1217442A1 (es)
HR (1) HRP20161611T1 (es)
HU (1) HUE031910T2 (es)
IL (1) IL240062B (es)
LT (1) LT2948156T (es)
MX (1) MX356851B (es)
NZ (1) NZ710583A (es)
PL (1) PL2948156T3 (es)
PT (1) PT2948156T (es)
RS (1) RS55418B1 (es)
RU (1) RU2635507C2 (es)
SG (1) SG11201505701WA (es)
SI (1) SI2948156T1 (es)
SM (1) SMT201700018B (es)
WO (1) WO2014114644A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551828B1 (es) * 2014-05-21 2016-09-12 Oxolife S.L. Composiciones alimentarias que comprenden sales de tungsteno (VI)
ES2639588B1 (es) * 2014-05-21 2018-09-06 Oxolife, S.L. Uso de una sal de tungsteno (VI) para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético
DK3173382T3 (da) * 2014-07-21 2023-03-13 Oxolife Sl Wolfram(vi)-salte til stimulering af fertilitet og reproduktion og til forbedring af effektiviteten af assisterede reproduktionsteknikker
EP4368577A1 (en) * 2022-11-08 2024-05-15 Oxolife, S.L. Process for the preparation of tungsten (vi) salt hydrates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328134A (en) * 1980-05-06 1982-05-04 Schally Andrew Victor Anorexigenic peptides
ES2108642B1 (es) * 1995-07-26 1998-08-16 Quimica Farm Bayer Sa Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
RU2141361C1 (ru) * 1998-03-12 1999-11-20 Пермская государственная медицинская академия Способ лечения ановуляторного бесплодия при ожирении
ES2187276B1 (es) * 2001-05-16 2004-08-01 Quimica Farmaceutica Bayer,S.A. Composiciones orales para el tratamiento de humanos obesos y no diabeticos.
AU2002368261A1 (en) * 2002-10-02 2004-04-23 Yeda Research And Development Co. Ltd. Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
RU2270684C1 (ru) * 2005-01-20 2006-02-27 Анатолий Григорьевич Гриценко Лекарственный препарат "витасорб"
US20080206356A1 (en) * 2005-07-29 2008-08-28 Universidad De Barcelona Pharmaceutical Compositions for the Treatment of Neurodegenerative Disorders
US20060100154A1 (en) * 2005-10-13 2006-05-11 Yeda Research And Development Co Long-acting gonadotropin-releasing hormone analogs and methods of use thereof

Also Published As

Publication number Publication date
HUE031910T2 (en) 2017-08-28
CL2015002047A1 (es) 2016-01-04
EP2948156B1 (en) 2016-10-26
RU2015135578A (ru) 2017-03-02
US20150359820A1 (en) 2015-12-17
AU2014209987B2 (en) 2016-09-01
MX356851B (es) 2018-06-18
CY1118287T1 (el) 2017-06-28
SMT201700018B (it) 2017-03-08
CA2898953C (en) 2018-01-02
PT2948156T (pt) 2016-11-30
AU2014209987A1 (en) 2016-01-21
SG11201505701WA (en) 2015-08-28
DK2948156T3 (da) 2017-01-02
HRP20161611T1 (hr) 2017-01-27
ES2478790A1 (es) 2014-07-22
IL240062B (en) 2018-11-29
JP6045721B2 (ja) 2016-12-14
NZ710583A (en) 2016-06-24
LT2948156T (lt) 2016-12-27
SI2948156T1 (sl) 2017-02-28
IL240062A0 (en) 2015-09-24
JP2016505057A (ja) 2016-02-18
KR102182563B1 (ko) 2020-11-25
MX2015009364A (es) 2016-03-08
ES2478790B1 (es) 2015-05-06
CN105188721A (zh) 2015-12-23
US9675638B2 (en) 2017-06-13
RU2635507C2 (ru) 2017-11-13
BR112015017483A2 (pt) 2017-07-11
CN105188721B (zh) 2017-10-31
EP2948156A1 (en) 2015-12-02
CA2898953A1 (en) 2014-07-31
HK1217442A1 (zh) 2017-01-13
RS55418B1 (sr) 2017-04-28
PL2948156T3 (pl) 2017-07-31
KR20150130992A (ko) 2015-11-24
WO2014114644A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2016003329A1 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
CR20170315A (es) Inhibridores bace 1 selectivos
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
CL2015003562A1 (es) Inhibidores de pi3 cinasa delta y gamma selectivos duales.
ES2641862T3 (es) Proceso para la elaboración de inhibidores de CCR3
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
ES2611776T3 (es) Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
ES2553423T3 (es) Viroterapia oncolítica para el tratamiento del sarcoma de Ewing
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
ES2585558T3 (es) Uso de sales de 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio en el tratamiento de una enfermedad cardiovascular
AR103484A1 (es) Triptólido y sus derivados en el tratamiento de tumores y patologías precancerosas de la piel
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis
ES2502140T1 (es) Comprimidos de liberación inmediata de rasagilina hemitartrato
ES2526935B2 (es) Compuestos para el tratamiento de infecciones por Leishmania
CL2016002844A1 (es) (r)-pirlindol o sus sales farmacéuticamente aceptables para uso en medicina.